pipette
ENEnglish

CD38-NAMPT-p21 signaling promotes stress adaptation in CLL

B. HAN, C. C. Chini, G. CICCIO LOPEZ, Y. HAMADA, A. PAULUS, A. CHANAN-KHAN, E. BRAGGIO, A. BERGLUND, E. N. Chini

Preprint

En palabras de los autores

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States, accounting for ~30% of new diagnoses and ~4,000 deaths annually. High CD38 expression is a well-established marker of poor prognosis, yet the mechanistic basis of CD38-mediated treatment failure has remained incompletely understood. Here, we demonstrate that CD38 functions not merely as a prognostic biomarker but as a metabolic and signaling regulator that equips CLL cells to withstand cytotoxic and hypoxic stress. Using MEC-1 cells engineered to express CD38, we identified a CD38-NAMPT-p21 survival axis that confers resistance to fludarabine and hypoxia. CD38 NADase activity promoted NAMPT upregulation and AKT activation and was associated with accumulation of cytoplasmic p21. This CD38-dependent phenotype was lost in cells expressing a catalytically inactive CD38 mutant and was also reversed by pharmacologic inhibition of NAMPT (FK866) or suppression of p21 (UC2288). Analysis of three independent single-cell RNA-sequencing datasets of primary CLL further showed that naturally occurring CD38-positive CLL cells exhibit increased NAMPT expression and related stress-response signaling. Analysis of larger primary CLL cohorts further linked NAMPT expression to AKT and hypoxia signatures, providing additional support for the relevance of this pathway in patient-derived CLL. Together, these findings identify CD38-NAMPT-p21 signaling as an important mechanism of stress adaptation in CLL and suggest that targeting NAD metabolism and p21-mediated survival pathways may represent a potential strategy for CD38-high disease.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.16.766865